Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Onda Website

Masanori Onda, M.D., Ph.D.

Selected Publications

1)  Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
J. Immunol. 193: 48-55, 2014.
[Journal]
2)  Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012.
[Journal]
3)  Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 108: 5742-7, 2011.
[Journal]
4)  Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, Hassan R, Pastan I.
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
J. Immunol. 177: 8822-34, 2006.
[Journal]
5)  Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Clin. Cancer Res. 12: 4225-31, 2006.
[Journal]
6)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
[Journal]
7)  Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I.
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Protein Eng. Des. Sel. 25: 1-6, 2012.
[Journal]
8)  Onda M.
Recombinant immunotoxins with low endotoxins for clinical and animal studies.
Methods Mol. Biol. 907: 627-43, 2012.
[Journal]
9)  Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.
Clin. Chem. Lab. Med. 50: 721-5, 2012.
[Journal]
10)  Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
Immunotoxins with decreased immunogenicity and improved activity.
Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011.
[Journal]
11)  Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH.
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Clin. Cancer Res. 17: 3697-705, 2011.
[Journal]
12)  Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I.
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
MAbs. 3: 479-86, 2011.
[Journal]
13)  Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I.
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Cancer Res. 70: 1082-9, 2010.
[Journal]
14)  Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I.
A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
J. Immunother. 33: 297-304, 2010.
[Journal]
15)  Onda M.
Reducing the immunogenicity of protein therapeutics.
Curr Drug Targets. 10: 131-9, 2009.
[Journal]
16)  Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I.
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 105: 11311-6, 2008.
[Journal]
17)  Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ.
Soluble CD22 as a tumor marker for hairy cell leukemia.
Blood. 112: 2272-7, 2008.
[Journal]
18)  Kobayashi T, Kai N, Kobayashi K, Fujiwara T, Akagawa K, Onda M, Kobayashi K.
Transient silencing of synaptic transmitter release from specific neuronal types by recombinant tetanus toxin light chain fused to antibody variable region.
J. Neurosci. Methods. 175: 125-32, 2008.
[Journal]
19)  Ise T, Das S, Nagata S, Maeda H, Lee Y, Onda M, Anver MR, Bera TK, Pastan I.
Expression of POTE protein in human testis detected by novel monoclonal antibodies.
Biochem Biophys Res Commun. 2007.
[Journal]
20)  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.
Mesothelin expression in human lung cancer.
Clin. Cancer Res. 13: 1571-5, 2007.
[Journal]
21)  Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, Gruhn B, Pastan I.
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Eur. J. Haematol. 79: 281-6, 2007.
[Journal]
22)  Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C.
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
Ann. Oncol. 17: 1615-9, 2006.
[Journal]
23)  Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Clin. Cancer Res. 12: 447-53, 2006.
[Journal]
24)  Egland KA, Liu XF, Squires S, Nagata S, Man YG, Bera TK, Onda M, Vincent JJ, Strausberg RL, Lee B, Pastan I.
High expression of a cytokeratin-associated protein in many cancers.
Proc. Natl. Acad. Sci. U.S.A. 103: 5929-34, 2006.
[Journal]
25)  Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, Pastan I, Wittig S, Pfaffendorf N, Voigt A, Zintl F, Gruhn B.
Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
Clin. Cancer Res. 12: 2434-41, 2006.
[Journal]
26)  Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO.
Mesothelin is shed from tumor cells.
Cancer Epidemiol. Biomarkers Prev. 15: 1751, 2006.
[Journal]
27)  Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Mol. Cancer. 5: 50, 2006.
[Journal]
28)  Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, Pastan IH.
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.
Proc. Natl. Acad. Sci. U.S.A. 102: 7946-51, 2005.
[Journal]
29)  Nagayoshi R, Nagai T, Matsushita K, Sato K, Sunahara N, Matsuda T, Nakamura T, Komiya S, Onda M, Matsuyama T.
Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages.
Arthritis Rheum. 52: 2666-75, 2005.
[Journal]
30)  Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I.
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Clin. Cancer Res. 11: 1545-50, 2005.
[Journal]
31)  Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I.
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Clin. Cancer Res. 11: 3814-20, 2005.
[Journal]
32)  Ho M, Kreitman RJ, Onda M, Pastan I.
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
J. Biol. Chem. 280: 607-17, 2005.
[Journal]
33)  Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I.
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
Clin. Cancer Res. 11: 5840-6, 2005.
[Journal]
34)  Onda M, Bruland ØS, Pastan I.
TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma.
Clin. Orthop. Relat. Res. 142-8, 2005.
[Journal]
35)  Onda M, Wang QC, Guo HF, Cheung NK, Pastan I.
In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Cancer Res. 64: 1419-24, 2004.
[Journal]
36)  Nagata S, Numata Y, Onda M, Ise T, Hahn Y, Lee B, Pastan I.
Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay.
J. Immunol. Methods. 292: 141-55, 2004.
[Journal]
37)  Gupta A, Onda M, Pastan I, Adhya S, Chaudhary VK.
High-density functional display of proteins on bacteriophage lambda.
J. Mol. Biol. 334: 241-54, 2003.
[Journal]
38)  Onda M, Vincent JJ, Lee B, Pastan I.
Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules.
Bioconjug. Chem. 14: 480-7, 2003.
[Journal]
39)  Nagata S, Onda M, Numata Y, Santora K, Beers R, Kreitman RJ, Pastan I.
Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
Clin. Cancer Res. 8: 2345-55, 2002.
[Journal]
40)  Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ.
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Mol. Cancer Ther. 1: 595-600, 2002.
[Journal]
41)  Onda M, Olafsen T, Tsutsumi Y, Bruland ØS ØS, Pastan I.
Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.
J Immunother. 24: 144-150, 2001.
[Journal]
42)  Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I.
Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
J. Immunother. 24: 144-50, 2001.
[Journal]
43)  Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, Lee B, Pastan I.
Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Cancer Res. 61: 5070-7, 2001.
[Journal]
44)  Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I.
Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
J. Immunol. 165: 7150-6, 2000.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.